Table III.
Distribution of mutations in rpoB, katG and inhA promoter region in 344 M. tuberculosis (MTB) isolates
| Drugs | DNA target | Nucleotide change | Amino acid change | RIFr/INHr (%) | RIFs/INHs (%) |
|---|---|---|---|---|---|
| RIF (n=198) | rpoB516* | GAC→GTC | Asp→Val | 15 (5.5) | 0 |
| rpoB526* | CAC→GAC | His→Asp | 36 (15.1) | 1 | |
| rpoB531* | TCG→TTG | Ser→Leu | 142 (71.7) | 2 | |
| rpoB516 and rpoB-526 | GAC→GTC and CAC→GAC | Asp→Val and His→Asp | 4 (2.0) | 0 | |
| rpoB526 and rpoB531 | CAC→GAC and TCG→TTG | His→Asp and Ser→Leu | 6 (3.0) | 0 | |
| Wild type$ | 5 (2.5) | 143 | |||
| Isoniazid (n=208) | katG 315* | AGC→ACC | Ser→Thr | 169 (81.2) | 2 |
| katG 315* | AGC→ACG | Ser→Asn | 8 (3.8) | 0 | |
| inhA-15* | C→T | NA | 28 (13.5) | 1 | |
| katG315 and inhA-15 | AGC→ACC and C→T | Ser→Thr and NA | 5 (2.4) | 0 | |
| Wild type$ | 3 (1.4) | 133 |
*Including double and triple mutations, $There were no mutations in katG 315 codon (Ser315Thr and Ser315Leu) and inhA promoter. NA, not applicable; RIF, rifampicin; INH, isoniazid